Patents by Inventor Craig Mullen

Craig Mullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Systems for Submitting and/or Processing Insurance Claims for Damaged Motor Vehicle Glass
    Publication number: 20210192455
    Abstract: Methods for submitting an insurance claim for damaged motor vehicle glass are provided that can include: receiving a plurality of images associated with motor vehicle glass at processing circuitry; performing image processing operations on each of the plurality of images to determine one or more of glass damage, glass type, and/or claim fraud; and submitting an insurance claim for motor vehicle glass repair or replace based on the glass type or damage, or flagging the claim as fraud. The present disclosure also provides a non-transitory computer readable storing instruction that when executed by a processor, causes a computer system to perform the following method.
    Type: Application
    Filed: March 10, 2021
    Publication date: June 24, 2021
    Applicant: Neural Claim System, Inc.
    Inventors: Jim Larson, Edward Zabasajja, Craig Mullen, Douglas J. Nelson
  • Methods and Systems for Submitting and/or Processing Insurance Claims for Damaged Motor Vehicle Glass
    Publication number: 20210073916
    Abstract: Methods for submitting an insurance claim for damaged motor vehicle glass are provided that can include: receiving a plurality of images associated with motor vehicle glass at processing circuitry; performing image processing operations on each of the plurality of images to determine one or more of glass damage, glass type, and/or claim fraud; and submitting an insurance claim for motor vehicle glass repair or replace based on the glass type or damage, or flagging the claim as fraud. The present disclosure also provides a non-transitory computer readable storing instruction that when executed by a processor, causes a computer system to perform the following method.
    Type: Application
    Filed: September 9, 2020
    Publication date: March 11, 2021
    Applicant: Neural Claim System, Inc.
    Inventors: Jim Larson, Edward Zabasajja, Craig Mullen, Douglas J. Nelson
  • Gene therapy by administration of genetically engineered CD34 cells obtained from cord blood
    Patent number: 6984379
    Abstract: A method of providing a therapeutic effect in a human patient which comprises administering to the patient CD34+ cells obtained from cord blood. The CD34+ cells have been engineered with at least one nucleic acid sequence encoding a therapeutic agent. Such CD34+ cells may be engineered by transducing the cells with a retroviral vector including the nucleic acid sequence encoding the therapeutic agent. This method has been applied in treating newborn infants suffering from ADA deficiency.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: January 10, 2006
    Assignees: Children's Hospital of LosAngeles, The United States of America as represented by the Department of Health and Human Services
    Inventors: Donald B. Kohn, R. Michael Blaese, Craig A. Mullen, Robert C. Moen
  • Cytosine deaminase negative selection system for gene transfer techniques and therapies
    Patent number: 5624830
    Abstract: The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by mammalian cells.The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolic 5-fluorouracil from 5-fluorocytosine.
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: April 29, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Craig A. Mullen, R. Michael Blaese
  • Cytosine deaminase negative selection system for gene transfer techniques and therapies
    Patent number: 5358866
    Abstract: The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by mammalian cells.The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolite 5-fluorouracil from 5-fluorocytosine.
    Type: Grant
    Filed: July 3, 1991
    Date of Patent: October 25, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Craig A. Mullen, R. Michael Blaese